In our penultimate video from ESMO 2024, pharmaphorum spoke with Dr Magda Meissner, consultant medical oncologist at the Velindre Cancer Centre and project lead for QuicDNA, about how a sim
The top court in the EU has ruled that the European Commission exceeded its authority in its investigation of the $8 billion merger between Illumina and Grail, albeit too late to halt the f
Element Biosciences’ bid to claim a slice of a DNA sequencing technology market dominated by Illumina has been helped by an impressive $277 million financing round backed by a wide range of
In a case that had been closely watched across multiple industries, Illumina chose to divest Grail in the light of legal action from the European Commission and the US Federal Trade Commiss
Illumina has said it will divest cancer detection company Grail, marking the end of a long-running antitrust dispute that has claimed the jobs of its former CEO and chair.
Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.